is all in $AAPL $TSLA and $PMCB
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I know a bunch of people who would buy a ton at .20, but I doubt we'll see even .60 again.
For pre-clinical biotech, above all invest based on the Management team.
Every stock has a story. OWC Pharma has Dr. Yehuda Baruch. Dr. Baruch was Director of the Israeli Medical Use of Cannabis Program from 2003-2012. He was tapped for the job, he didn't seek it out. In fact, he wasn't truly pro MMJ until around 2005 when one of his cancer patients thank Dr. Baruch for letting him live out his final days with the dignity afforded the MMJ treatments.
As of 2012, Dr. Baruch had personally overseen the MMJ treatments of almost 14,000 patients.
Furthermore, OWC Pharma has been doing testing not just on CBD/THC combinations, but on combinations of "at least 8 cannabinoids and a few bioflavonoids". This is light years ahead of every other firm. (There is another cannabis biotech company, InMed, that is doing interesting things with the other cannabinoids today, but OWC Pharm has been testing these compounds for years. Years in biotech research is like dog years to human years.)
They key takeaway is OWCP is cannabis biotech. Over the long term, the big money is in tested, proven, precise, scientific delivery systems.
No legitimate doctor wants to tell a patient to "take two puffs and call me in the morning".
And taking CBD oils is akin to carpet bombing. What doctors and the FDA want is precise amounts of cannabinoids, in proven ratios, delivered to the blood stream. MMJ CBD oil is currently about carpet bombing, with OWC Pharma it will be about laser-guided missiles.
Do you know who Sacha Baron Cohen is? Da Ali G show?
Sacha gets dumb*ss public figures to sit through truly absurd Q&As. It's freaking hysterical. So he tries it on Trump, and Trump looks at him and gets up and says interview over. Other people go on and on for 30 minutes, trying not to offend Da Ali G, but Trump saw through the con in about 5 seconds. Sure it's on youtube.
I'm a former MM, although I never made markets in any stocks/ETFs that traded below $40 a share.
MAXM as of 7:35 has 100 at $2.00. Yes, they are sitting out.
ARCA (great guys btw) have 3200 at 0.80 as of 9:01. They were at $1 earlier.
VFIN's $1.00 is from 1/3, so they are obviously sitting out too.
INTL has 100 at $1.27 as of 7:35. Sitting it out, or a vote of confidence?
There are all sorts of manipulations that MMs can do. If you look closely, you can tell if they are just trading, acquiring or disposing. I don't have a Bloomberg terminal so I can't do in depth research, but it seems to me most of them are actively trading the stock and some are actually acquiring.
Also MM"s that want to stay out of active trading usually place their bids and ask a bit away out of the action..I saw people here yesterday commenting on where these were and it was a sign of what is to come....again...not true...
I am a former broker/agent, and have my series 7 securities license. I taught people how to daytrade in the past and understand how the markets work and the games mm's play. A good friend of mine works for Goldman Sachs...he told me that a lot of the times during the day MM's specifically go after intra day traders to shake shares lose..
In his inauguration speech, Trump said:
"Do not allow anyone to tell you that it cannot be done. No challenge can match the heart and fight and spirit of America. We will not fail. Our country will thrive and prosper again. We stand at the birth of a new millennium, ready to unlock the mysteries of space, to free the earth from the miseries of disease and to harness the energies, industries and technologies of tomorrow. A new national pride will stir ourselves, lift our sights and heal our divisions. It’s time to remember that old wisdom our soldiers will never forget -- that whether we are black or brown or white, we all bleed the same red blood of patriots."
I'd like to think he was alluding to MMJ, as clinical trials have shown promising results with CBD killing cancer cells among other health benefits.
Short interest is waning:
http://otcshortreport.com/?index=OWCP&action=view
A company that employees fulltime and professional stock analysts has acquired nearly 500K of PMCB.
Top Institutional Holders
Holder Shares Date Reported % Out Value
Fisher Asset Management, LLC 497,604 Dec 30, 2016 0.06% 74,640
Older article, but a great read for anyone interested in any MMJ stock. Interview with Dr. Baruch:
http://ireadculture.com/blending-the-private-and-public-to-advance-cannabis-use/
Barchart showing TSLA as Top 1% and 100% Buy.
https://www.barchart.com/stocks/quotes/TSLA
There's at least one fund that has a stake in PMCB. It's not easy to fool institutional analysts.
http://finance.yahoo.com/quote/PMCB/holders?p=PMCB
Do you read Hebrew? All their studies are in Hebrew, yes?
More sensible to compare OWCP and AXIM, IMHO.
Are you looking at L2? Eight MMs have Asks at $1 and above. Granted, we're talking about 100 share blocks for the most part, but the writing is on the wall.
I'm loving the daily chart today, solid support now at .72. I'll take a few sideways days on the march up to dollar land.
I've got my eye on a Tesla : )
Careful! Stocks have popped from .50 to $10. If you have $5 you will be picked off on the way up. Dangerous to protect your shares like that with biotech companies, since buyout offers can happen at any time.
Right on! I'm all for thorough DD and when I've told people to check out the stock they of course start with a Google search and they end up right on investorshub quickly.
It is off putting to some people to see "hype hype hype".
Personally, on the basis of the psoriasis creme alone I'm putting a valuation of $2-4 on this stock by Q3. Interestingly, I put about the same value on AXIM right now and that thing is trading at $13-15.
So, I'm going to be thrilled with $2, but with the smallish float I can see it being pushed up higher. Everyone is looking for the next GWPH and noone wants to miss the boat.
Just increased my position to 100,000 shares. Go $PMCB!
Dr Sanjay Gupta's youtube video re "Charlotte's Web"
“I wanted to see if I could do research on cannabis in Israel – with Prof. Yehuda Baruch.”
They haven't split since 1999, so it's anyone's guess.
Barchart rating for $IMLFF: 96% BUY
https://www.barchart.com/stocks/quotes/IMLFF
Credit Suisse raised their price target on $AMZN to $1,000.
https://www.com-unik.info/2017/01/16/amazon-com-inc-amzn-price-target-raised-to-1000-00.html
Top law firm Foley on how Trump could change the FDA in the first 100 days
http://www.mondaq.com/article.asp?article_id=562318
I believe that test listed on clinicaltrails.gov is to satisfy requirements to sell in US MMJ States. The March deadlines posted below are for separate Israel tests, I think, which I believe will allow for sales to start in EU.
Psoriasis (Skin Disease)
• Pharma-grade ‘challenge tests’ successfully completed
05/2016
• Safety study at Sheba, Tel Hashomer under approved
IRB (Helsinki) protocol. To be completed 3/2017
• In-vitro psoriasis efficacy study of the topical crème to
be completed by 3/2017
• IP owned by OWCP
• EXPECTED MARKET READINESS : Q2/2017
It's just a blurb atm:
"MSCI Inc initiates coverage for OWC PHARMACEUTICAL COM USD0.001 with 3 recommendation.
BY Investars Analyst Actions - public
— 7:19 AM ET 01/23/2017
On January 23, 2017 MSCI Inc initiated coverage for OWC PHARMACEUTICAL COM USD0.001 with a 3 recommendation."
Yup, just saw that on Fidelity's News feed!
Did a lot of DD on this very promising company this weekend and was pleased to get my total holdings to 50,000 this morning.
Increased my holding to 50,000 shares. Very promising company!
I guarantee you that a case study comparison between OWCP and GWPH will happen this year in various top MBA programs.
The way I see it, GWPH went the traditional biotech start up route: raise massive capital with a large public offering, then burn through the money and hope to get FDA Phase 3 approval before the money runs out. That's the typical biotech game plan. People invest in 10 biotech IPOs because they know long term if just one gets to Phase 3 it will pay the cost of the other 9 investments.
OWCP, on the other hand, laid the ground work with their 8 IP patents and then after extensive testing looked at their pipeline and determined the one item, psoriasis creme, which would lead to immediate revenue. The revenue from the psoriasis creme will bring in the estimated $2-4 Million a month that OWCP will use to build out the other revenue pipelines. FDA trials are expensive! Also, OWCP's game plan has been all along to do all their research in the MMJ friendly Israel system and only engage the FDA at the right time for "Orphan" drug status, which is a fast track system. This will allow OWCP to jump into the FDA approval process at lower overall cost.
Look at the salary's and rents GWPH has been paying. Compare that to the miniscule amount OWCP pays itself. OWCP has played it very carefully and cautiously and they have done everything in their power to preserve shareholder value.
Do your own DD, but personally I'm not selling a single share until we smash the $20s.
Psoriasis phase 3 studies are due March 2017, and agreements have already been signed to begin production and sales in EU and US MMJ states in Q2.
I'm basing my valuation of OWCP on the expected revenue from the psoriasis cream in Q2, Q3, and Q4.
Psoriasis (Skin Disease)
• Pharma-grade ‘challenge tests’ successfully completed
05/2016
• Safety study at Sheba, Tel Hashomer under approved
IRB (Helsinki) protocol. To be completed 3/2017
• In-vitro psoriasis efficacy study of the topical crème to
be completed by 3/2017
• IP owned by OWCP
• EXPECTED MARKET READINESS : Q2/2017
Multiple Myeloma (Cancer)
• Designed to be an Orphan Disease study approved by the FDA
• In-vitro study completed 06/2015 – Cannabis kills the MM cancer cells
• Pre-clinic study on mice completed 12/2015 – calibration phase for dosage,
found most effective ratio of active cannabinoids THC/CBD
• In-vitro study for a combination of 4 approved drugs with cannabis completed
05/2016 – promising results
• Pre-clinic study for the most effective combination on mice with new cannabis
extracts. On-going testing.
• SUBJECT TO ACHIEVING SCIENTIFIC MILESTONES THE COMPANY WILL
SUBMITT AN APPLICATION WITH THE FDA FOR AN ORPHAN DISEASE
DESIGNATION
The articles I've seen mentioning OWCP of late seem to be written to draw views to the websites. If someone was being paid to promote the company, it would have to be disclosed in a filing and there would also have to be a disclaimer at the bottom of the "article".
So my mother-in-law travels to Israel every year to stock up on a cannabis-based cream for her Rheumatoid Arthritis. CBD works on all sorts of ailments. It's not toxic.
When a new "drug" is tested by the FDA the first concern is to determine if the new drug is harmful. OWCP's products are going to breeze through that stage of testing. Then it goes to efficacy testing. The time spent at that stage is less about "does it work", and more about what ratio of CBD/THC is MOST effective.
In any event, look at the prices of pre clinical biotech companies that have one or two prospects in the pipeline. Those are valued on models that weigh likelihood of FDA approval, likely percent of market share, and scarcity of other medications for that particular ailment.
OWCP will have a complex valuation model because the pipeline is so robust.
Take a look at the revenue pipeline. I don't think $20 is unrealistic within 1 year.
In 2 years OWCP could have:
A sublingual tablet to treat Multiple Myeloma cancer.
A sublingual tablet to treat PTSD.
A sublingual tablet to treat Migraines.
A sublingual tablet to treat Fibromyalgia.
A topical cream to treat Psoriasis. (Revenue starting in Q3)
A topical cream to treat Acne.
A topical cream to treat Basal Cell Carcinoma.
A topical cream to treat Atopic Dermatitis.
Government consulting contracts. (3 contracts already signed)
Licensing agreements on their tablet, cream, and nasal spray delivery systems.
Look at the valuations of AXIM and GWPH and compare the pipelines of those companies to OWCP's pipeline. Does it really seem correct to compare OWCP with AXIM and GWPH?
The million dollar question is, knowing what is on the very bright horizon for OWCP, what will analysts' valuation be. $20 seems very reasonable to me.
In his inauguration speech, Trump said:
"Do not allow anyone to tell you that it cannot be done. No challenge can match the heart and fight and spirit of America. We will not fail. Our country will thrive and prosper again. We stand at the birth of a new millennium, ready to unlock the mysteries of space, to free the earth from the miseries of disease and to harness the energies, industries and technologies of tomorrow. A new national pride will stir ourselves, lift our sights and heal our divisions. It’s time to remember that old wisdom our soldiers will never forget -- that whether we are black or brown or white, we all bleed the same red blood of patriots."
I'd like to think he was alluding to MMJ, as clinical trials have shown promising results with CBD killing cancer cells.
Noticed that too. Annual shareholders letter said results due end of Jan, but that PowerPoint says March.
They can certainly announce the consulting contracts with (what I believe are three States), that's great press and also a small amount of revenue.
And here's exactly how we'll get to $100 PPS (my bold):
Multiple Myeloma (Cancer)
• Designed to be an Orphan Disease study approved by the FDA
• In-vitro study completed 06/2015 – Cannabis kills the MM cancer cells
• Pre-clinic study on mice completed 12/2015 – calibration phase for dosage,
found most effective ratio of active cannabinoids THC/CBD
• In-vitro study for a combination of 4 approved drugs with cannabis completed
05/2016 – promising results
• Pre-clinic study for the most effective combination on mice with new cannabis
extracts. On-going testing.
• SUBJECT TO ACHIEVING SCIENTIFIC MILESTONES THE COMPANY WILL
SUBMITT AN APPLICATION WITH THE FDA FOR AN ORPHAN DISEASE
DESIGNATION
They've already signed 3 consulting contracts! With States, I believe (my bold):
International Consultancy
• Covering expertise with growers, breeds,
patients treatments, educational
programs, regulation and more.
• Signed 3 agreements to consult in the US.
http://www.owcpharma.com/wp-content/uploads/2017/01/OWC-PPT-1-2017-FINAL.pdf
I swear these guys are absolutely brilliant. Typical biotech has to raise $30 Million and then burns through that hoping to get approval before the money runs out.
OWCP developed a revenue stream first to fund the expensive FDA trials later. Genius!
The planning, formation and development of OWCP will be a case study taught to MBA students for years to come.
From page 10 (my emphasis):
IP-owned developed of new innovative and tested delivery
systems.
• Two products ready to market:
• Sublingual Soluble tablet: replacement of smoking, pain
treatment. more than 10 million potential patients in the approved
MMJ states.
• Topical crème: Treatment for different skin diseases starting with
tested psoriasis. ~8 Million Psoriasis patients US & Canada (2.5% of
population), 3 years potential is 2-4 millions monthly income
(following current market prices)